Asthma Surveillance Using Medicaid Administrative Data

Abstract

Connecticut, Michigan, and New York have successfully used Medicaid administrative data to conduct surveillance of asthma prevalence, related health service utilization and costs, and quality of asthma care. Since these assessments utilize beneficiary-level data, a wide range of population-based summaries is feasible. Opportunities exist to build upon the collective experiences of these three states to establish a national framework for asthma surveillance using Medicaid administrative data. This framework could be designed to respond to each state's unique data considerations and asthma management priorities, while establishing standardized criteria to enhance the comparability of asthma surveillance data among states. Importantly, a common asthma case definition using comparable methods is necessary to enable comparisons of prevalence estimates between states. Case definitions that could serve as the foundation for such a framework are presented. Mechanisms to foster sharing of methodologies and experiences will be instrumental for broad implementation across states. This collaboration will be of increasing importance as states experience mounting financial pressures due to increasing Medicaid enrollment and dwindling resources.

Estimating the completeness of physician billing claims for diabetes case ascertainment using population-based prescription drug data

“…1,2 These data are popular for several reasons: they are timely; they contain information about numerous individuals; and they are relatively inexpensive to access and use. Electronic physician claims data, which capture billing records or claims for outpatient physician contacts with patients, are a rich resource for research and surveillance because the vast majority of people with a chronic disease will maintain regular contact with a physician for disease management and treatment.…”

Antileukotriene Agents Versus Long‐Acting Beta‐Agonists in Older Adults with Persistent Asthma: A Comparison of Add‐On Therapies

“…The data source for this study consisted of 2009–10 Medicare fee‐for‐service (FFS) medical claims (Parts A and B), Part D prescription drug event data, and Beneficiary Summary Files obtained from the Centers for Medicare and Medicaid Services for a 10% random sample of beneficiaries continuously enrolled in Parts A, B, and D in 2009. The sample consisted of beneficiaries who were continuously enrolled in FFS Medicare Parts A and B with Part D coverage from January 1, 2009, to December 31, 2010; were aged 66 and older as of January 1, 2009; met criteria for having an asthma diagnosis as of January 1, 2009, according to the Centers for Medicare and Medicaid Services Chronic Conditions Data Warehouse (CCW) algorithm for detecting asthma in FFS Medicare beneficiaries; were being treated exclusively with ICS + LABA or ICS + LTRA during 2009–10; and had at least 4 months of “wash in” in which no other asthma treatments were used before the time during which they were exclusively treated with ICS + LABA or ICS + LTRA. This wash‐in period was used to eliminate any residual effect from prior use of the other add‐on therapies that could potentially confound results.…”

Estimation de l'exhaustivité des données de facturation des médecins pour la détermination des cas de diabète au moyen des données sur les médicaments d'ordonnance

“…Les données administratives électroniques sur la santé sont largement utilisées au Canada et ailleurs dans le monde pour mener des recherches et exercer une surveillance sur les maladies chroniques à l'échelle des populations 1,2 . Ces données sont appréciées pour plusieurs raisons : elles sont à jour, elles contiennent des…”